Skip to main content
Clinical Criteria Updates Notification - February 2021
May 17, 2021
Medical Policy & Clinical Guidelines

Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

On February 19, 2021, and March 4, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Healthy Blue + Medicare. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, email druglist@ingenio-rx.com.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
EFFECTIVE DATEDOCUMENT NUMBERCLINICAL CRITERIA TITLENEW OR REVISED
August 1, 2021ING-CC-0186*Margenza (margetuximab-cmkb)New
August 1, 2021ING-CC-0187*Breyanzi (lisocabtagene maraleucel)New
August 1, 2021ING-CC-0188*Imcivree (setmelanotide)New
August 1, 2021ING-CC-0189*Amondys 45 (casimersen)New
August 1, 2021ING-CC-0190*Nulibry (fosdenopterin)New
August 1, 2021ING-CC-0086*Spravato (esketamine) Nasal SprayRevised
August 1, 2021ING-CC-0158Enhertu (fam-trastuzumab deruxtecan-nxki)Revised
EFFECTIVE DATEDOCUMENT NUMBERCLINICAL CRITERIA TITLENEW OR REVISED
August 1, 2021ING-CC-0167Rituximab Agents for Oncologic Indications Step TherapyRevised
August 1, 2021ING-CC-0157*Padcev (enfortumab vedotin)Revised
August 1, 2021ING-CC-0125*Opdivo (nivolumab)Revised
August 1, 2021ING-CC-0119*Yervoy (ipilimumab)Revised
August 1, 2021ING-CC-0099Abraxane (paclitaxel, protein bound)Revised
August 1, 2021ING-CC-0094*Pemetrexed Agents (Alimta, Pemfexy)Revised
August 1, 2021ING-CC-0123*Cyramza (ramucirumab)Revised
August 1, 2021ING-CC-0115*Kadcyla (ado-trastuzumab)Revised
August 1, 2021ING-CC-0033*Xolair (omalizumab)Revised
August 1, 2021ING-CC-0043Monoclonal Antibodies to Interleukin-5Revised
August 1, 2021ING-CC-0067*Prostacyclin Infusion and Inhalation TherapyRevised
August 1, 2021ING-CC-0075*Rituximab Agents for Non-Oncologic IndicationsRevised
August 1, 2021ING-CC-0034*Hereditary Angioedema AgentsRevised
August 1, 2021ING-CC-0028*Benlysta (belimumab)Revised

Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.

Information in other languages: Español   中文   Tiếng Việt   한국어   Français   العَرَبِيَّة   Hmoob   ру́сский   Tagalog   ગુજરાતી   ភាសាខ្មែរ   Deutsch   हिन्दी   ລາວ   日本語

© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.